Skip to main content

Year: 2025

Plug Power Installs 5MW GenEco Electrolyzer with Cleanergy Solutions Namibia for Africa’s First Fully Integrated Green Hydrogen Facility

Cleanergy Solutions Namibia project at Hydrogen Dune site combines solar-powered hydrogen production, public refueling station, and support infrastructure, marking milestone for Africa’s emerging hydrogen market SLINGERLANDS, N.Y., Dec. 17, 2025 (GLOBE NEWSWIRE) — Plug Power Inc. (NASDAQ: PLUG), a global leader in comprehensive hydrogen solutions for the hydrogen economy, today announced it has successfully installed a 5MW GenEco electrolyzer system for Cleanergy Solutions Namibia’s groundbreaking green hydrogen project. The Walvis Bay project plant, which officially opened in September, represents Africa’s first fully integrated commercial green hydrogen facility and will serve as the foundation for expanding hydrogen mobility across Namibia and neighboring markets. Plug’s PEM GenEco electrolyzer is integrated directly at Cleanergy...

Continue reading

Moleculin Announces Positive Results from Phase 1 Clinical Trial Evaluating WP1066 for the Treatment of Pediatric Recurrent Malignant Brain Tumors

Emory University physician-sponsored clinical trial conducted at the Aflac Cancer and Blood Disorders Center at Children’s Healthcare of Atlanta Results demonstrated WP1066 induces anti-tumor immune responses and were recently published in the Journal of Clinical Investigation Insight WP1066 found to be safe and effective, warranting a Phase 2 trial HOUSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced positive results from the Emory University physician-sponsored Phase 1 clinical trial conducted at the Aflac Cancer and Blood Disorders Center at Children’s Healthcare of Atlanta led by pediatric oncologist, Tobey MacDonald, MD, who discovered STAT3 is critical to certain childhood brain tumors and currently serves as Professor of Pediatrics and Director...

Continue reading

Atos Strengthens Leadership in Data & AI in Spain as the Country Moves Towards AI at Scale

Press Release         Atos Strengthens Leadership in Data & AI in Spain as the Country Moves Towards AI at Scale Penteo, a leading Spanish market analyst, highlights Atos’ Expertise in a recent report as AI left experimental phase to become a core element of business strategy and competitiveness in the country and throughout Europe Paris, France, December 17, 2025 – Atos, a global leader in AI-powered digital transformation, has reinforced its position as a leader in Data & Artificial Intelligence (AI) solutions in Spain, according to the latest independent analysis by Penteo, a leading technology market analyst in Spain and Portugal. In Penteo’s latest “Data & AI 2025 Universe Report”, Atos stands out for guiding organizations in the responsible and scalable adoption of AI focusing on real business impact, at a time when...

Continue reading

VYNE Therapeutics and Yarrow Bioscience Announce Merger Agreement 

Following closing, combined company plans to progress Yarrow’s lead program, YB-101, a potentially first-in-class anti-thyroid-stimulating hormone receptor (“TSHR”) antibody for Graves’ disease (“GD”) and thyroid eye disease (“TED”) Yarrow Bioscience is the seventh biotechnology company founded by RTW Investments and plans to advance in-licensed asset YB-101 (also known as GS-098) into a U.S.-based Phase 1b/2b trial in patients with GD in the first half of 2026; a Phase 1 trial in TED is being conducted in China by partner Changchun GeneScience Pharmaceutical Co., Ltd (“GenSci”) Pre-closing private financings totaling approximately $200 million expected to fund operations into 2028 Companies to hold conference call on December 17, 2025 at 8:30AM EDTNEW YORK, Dec. 17, 2025 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE)...

Continue reading

E.F. Hutton Advises on Strategic Merger Between Apimeds and MindWave, Aligning Biotech Growth with AI-Enabled Financial Innovation

NEW YORK, Dec. 17, 2025 (GLOBE NEWSWIRE) — E.F. Hutton is proud to have served as an Exclusive M&A Advisor in the recently completed merger between Apimeds Pharmaceuticals US Inc. (NYSE American: APUS) and Mindwave Innovations Inc. The merger brings together a biotech development platform with an AI-powered digital treasury infrastructure supported by a $100 million PIPE commitment, for which E.F. Hutton acted as Placement Agent. E.F. Hutton’s involvement underscores its commitment to advancing the combined company’s strategic growth across late-stage biotech development and institutional Digital Asset Treasury Solutions. E.F. Hutton worked closely with both companies to shape the transaction framework, coordinate investor participation, and guide the capital raise through a complex diligence and negotiation process. The merger...

Continue reading

HUB Cyber Security (Nasdaq: HUBC) Announces First Half 2025 Results and Declares Its Strategic Mission: Build the Global Trust Infrastructure for the Digital Economy

TEL AVIV, Israel, Dec. 17, 2025 (GLOBE NEWSWIRE) — HUB Cyber Security Ltd. (Nasdaq: HUBC) (“HUB” or the “Company”) today announced selected financial results for the six-month period ended June 30, 2025, and outlined the Company’s accelerated strategy to become the global trust infrastructure for identity, secure data, and regulated AI across industries and national ecosystems. The Company will announce the timing of its business update call in due course. The results reflect meaningful progress in strengthening the Company’s operating profile, improving margin structure, and advancing balance-sheet stabilization initiatives. Financial and Operational HighlightsRevenue of $15.1 million for the first half of 2025. Gross Margin surged to 23%, up from 10% last year, following a structural shift that more than doubles HUB’s margin...

Continue reading

Progressive Reports November 2025 Results

MAYFIELD VILLAGE, OHIO, Dec. 17, 2025 (GLOBE NEWSWIRE) — The Progressive Corporation (NYSE:PGR) today reported the following results for the month ended November 30, 2025:  November(millions, except per share amounts and ratios; unaudited)   2025     2024   ChangeNet premiums written $ 6,193   $ 5,563   11   %Net premiums earned $ 6,894   $ 6,040   14   %Net income $ 958   $ 1,006   (5 ) %Per share available to common shareholders $ 1.63   $ 1.71   (5 ) %Total pretax net realized gains (losses) on securities $ 32   $ 175   (82 ) %Combined ratio   87.1     85.6   1.5   pts.Average diluted equivalent common shares   588.0     587.7   0   %  November 30,(thousands; unaudited) 2025   2024   % ChangePolicies in Force          Personal Lines          Agency – auto 10,713   9,700   10Direct...

Continue reading

Eldorado Gold Purchases Additional Shares in Amex Exploration

VANCOUVER, British Columbia, Dec. 17, 2025 (GLOBE NEWSWIRE) — Eldorado Gold Corporation (TSX: ELD, NYSE: EGO) (“Eldorado” or the “Company”) Eldorado Gold Corporation (“Eldorado”) advises that effective December 17, 2025, it has acquired ownership of 14,868,200 common shares (“Shares”) of Amex Exploration Inc. (“Amex”) at a price per Share of C$4.00, for total consideration of C$59,472,800, pursuant to a private agreement with a third party (the “Share Acquisition”). Prior to the Share Acquisition, Eldorado beneficially owned and controlled 23,758,130 common shares of the Company and 207,000 common share purchase warrants, each warrant entitling the holder to acquire one Share (the “Warrants”), representing approximately 16.77% of the outstanding common shares on a non-diluted basis and approximately 16.89% on a partially...

Continue reading

Rexel: Denial of rumors regarding Rexel acquisition

Denial of rumors regarding Rexel acquisition In line with its communication practices, the company does not intend to comment on market rumors. Following the article published in La Lettre today, the company would nevertheless like to clarify that, as of today, it has no ongoing contacts and is not conducting any negotiations with potential buyers. The company remains focused on executing its strategy and creating value for all of its stakeholders.         ABOUT REXEL GROUP Rexel, worldwide expert in the multichannel professional distribution of products and services for the energy world, addresses three main markets: residential, non-residential, and industrial. The Group supports its residential, non-residential, and industrial customers by providing a tailored and scalable range of products and services in energy management for construction,...

Continue reading

Renowned AI Expert Xi Chen Joins Compass Lexecon

WASHINGTON, Dec. 17, 2025 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced that Dr. Xi Chen, Professor and Andre Meyer Faculty Fellow at the Department of Technology, Operations and Statistics at the New York University Stern School of Business, has affiliated with its subsidiary Compass Lexecon. Dr. Chen, who is based in New York, is an award-winning expert in machine learning, artificial intelligence, quantitative economics and digital platforms. He has collaborated on major AI and platform-related projects with Google, Meta, Adobe, Bloomberg, Alibaba and JPMorganChase, covering digital markets, algorithmic recommendation, privacy and financial forecasting. In his role at Compass Lexecon, Dr. Chen will work closely on issues central to today’s litigation landscape, including digital market competition, online...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.